Streetbeat News

Analyst Ratings

AZN

BMY

FUSN

LLY

Fusion Pharmaceuticals Inc (FUSN) is highlighted as a key player in the targeted radiopharmaceutical therapy (TRT) space by Oppenheimer, especially after recent acquisitions by Bristol Myers Squibb & Co (BMY) and Eli Lilly And Co (LLY). Fusion's partnership with AstraZeneca Plc (AZN) on advancing targeted radiotherapies and a profit-sharing agreement could position AstraZeneca for future acquisitions. Raymond James upgraded Fusion's stock from Outperform to Strong Buy with a price target of $15.

Portfolio Pulse from Vandana Singh

December 27, 2023 | 5:42 pm

AAPL

CRWD

META

MSFT

NVDA

Gene Munster of Deepwater Asset Management predicts a significant bull market in tech stocks driven by AI, similar to the 1990s dot-com era. He sees Nvidia, Microsoft, and Meta as key beneficiaries, with smaller players like CrowdStrike and Nubank also having potential due to their innovative AI approaches. Munster is bullish on Meta's AI-driven growth and anticipates Apple to make strides in AI. However, he cautions against the potential for a 'bubble-like' environment in AI and emphasizes the need for nimble strategies.

Portfolio Pulse from Piero Cingari

December 27, 2023 | 5:29 pm

GRCL

Wells Fargo analyst Yanan Zhu has downgraded Gracell Biotechnologies (GRCL) from Overweight to Equal-Weight and set a price target of $10. The downgrade reflects a change in the bank's view on the stock's future performance.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 5:27 pm

CVRX

Lake Street has reaffirmed its Buy rating on CVRx (NASDAQ:CVRX) and increased its price target from $21.00 to $32.00. CVRx's stock is currently trading at $31.44, up 1.29% over the last 24 hours. The new price target suggests a modest 1.78% potential upside. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, with its main product, Barostim, targeting the Autonomic Nervous System to treat heart failure.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 5:00 pm

CART

Wedbush has maintained a Neutral rating for Maplebear (NASDAQ:CART), also known as Instacart, and lowered its price target from $30.00 to $26.00. Despite this, Maplebear's shares have seen a slight increase of 0.08% over the last 24 hours, trading at $24.21. The new price target suggests a potential upside of 7.39% from the current share price. Instacart operates as an online grocery pickup and delivery service in the US and Canada, earning revenue through transaction fees and advertising.

Portfolio Pulse from Benzinga Insights

December 27, 2023 | 5:00 pm

TSLA

Tesla Inc (NASDAQ:TSLA) is preparing to launch a new version of the Model Y, targeting mass production by mid-2024. The revamped Model Y will feature significant changes to both interior and exterior, with initial production expected at Giga Shanghai after upgrades. This move comes as Tesla faces increased competition, particularly from BYD, which may surpass Tesla in global EV sales. Tesla's Shanghai factory is crucial, accounting for over half of global deliveries and Model Ys representing a significant portion of China sales. Morgan Stanley analyst Adam Jonas maintains an Overweight rating on Tesla with a $380 price target.

Portfolio Pulse from Adam Eckert

December 27, 2023 | 4:47 pm

BLTE

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Belite Bio (NASDAQ:BLTE) and maintained a price target of $59. This endorsement from the analyst could influence investor sentiment and potentially impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:45 pm

CYTK

HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $58 to $94, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:36 pm

VERA

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $25 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:21 pm

ORGO

Shares of Organogenesis Holdings are trading higher following BTIG's reaffirmation of a Buy rating and an increase in the price target from $4 to $6.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 4:18 pm